tetano
Editor, Senior Moderator
Int J Biol Macromol
. 2023 Feb 15;123635.
doi: 10.1016/j.ijbiomac.2023.123635. Online ahead of print.
Bidirectional and persistent immunomodulation of Astragalus polysaccharide as an adjuvant of influenza and recombinant SARS-CoV-2 vaccine
Danping Zhao[SUP] 1 [/SUP], Xiuhong Chen[SUP] 1 [/SUP], Linyuan Wang[SUP] 2 [/SUP], Jianjun Zhang[SUP] 3 [/SUP], Zhongpeng Zhao[SUP] 4 [/SUP], Na Yue[SUP] 5 [/SUP], Yingli Zhu[SUP] 1 [/SUP], Wenting Fei[SUP] 1 [/SUP], Xinyu Li[SUP] 6 [/SUP], Lingyun Tan[SUP] 6 [/SUP], Wei He[SUP] 6 [/SUP]
Affiliations
Abstract
Respiratory viral infections, such as coronavirus disease of 2019 (COVID-19) and influenza, cause significant morbidity and mortality and have become a worldwide public health concern with tremendous economic and societal burdens. Vaccination is a major strategy for preventing infections. However, some new vaccines have an unmet need for impairing responses in certain individuals, especially COVID-19 vaccines, despite ongoing vaccine and adjuvant research. Here, we evaluated the effectiveness of Astragalus polysaccharide (APS), a bioactive polysaccharide extracted from the traditional Chinese herb Astragalus membranaceus as an immune adjuvant to regulate the efficacy of influenza split vaccine (ISV) and recombinant severe acute respiratory syndrome (SARS)-Cov-2 vaccine in mice. Our data indicated that APS as an adjuvant can facilitate the induction of high levels of hemagglutination inhibition (HAI) titer and specific antibody immunoglobulin G (IgG) and confer protection against the lethal challenge of influenza A viruses, including increased survival and amelioration of weight loss in mice immunized with the ISV. RNA sequencing (RNA-seq) analysis revealed that the NF-κB and Fc gamma R-mediated phagocytosis signaling pathways are essential for the immune response of mice immunized with the recombinant SARS-Cov-2 vaccine (RSV). Another important finding was that bidirectional immunomodulation of APS on cellular and humoral immunity was observed, and APS-adjuvant-induced antibodies persisted at a high level for at least 20 weeks. These findings suggest that APS is a potent adjuvant for influenza and COVID-19 vaccines, and has the advantages of bidirectional immunoregulation and persistent immunity.
Keywords: Adjuvant; Astragalus polysaccharide; Immunomodulation; Influenza vaccine; Recombinant SARS-CoV-2 vaccine.
. 2023 Feb 15;123635.
doi: 10.1016/j.ijbiomac.2023.123635. Online ahead of print.
Bidirectional and persistent immunomodulation of Astragalus polysaccharide as an adjuvant of influenza and recombinant SARS-CoV-2 vaccine
Danping Zhao[SUP] 1 [/SUP], Xiuhong Chen[SUP] 1 [/SUP], Linyuan Wang[SUP] 2 [/SUP], Jianjun Zhang[SUP] 3 [/SUP], Zhongpeng Zhao[SUP] 4 [/SUP], Na Yue[SUP] 5 [/SUP], Yingli Zhu[SUP] 1 [/SUP], Wenting Fei[SUP] 1 [/SUP], Xinyu Li[SUP] 6 [/SUP], Lingyun Tan[SUP] 6 [/SUP], Wei He[SUP] 6 [/SUP]
Affiliations
- PMID: 36801224
- DOI: 10.1016/j.ijbiomac.2023.123635
Abstract
Respiratory viral infections, such as coronavirus disease of 2019 (COVID-19) and influenza, cause significant morbidity and mortality and have become a worldwide public health concern with tremendous economic and societal burdens. Vaccination is a major strategy for preventing infections. However, some new vaccines have an unmet need for impairing responses in certain individuals, especially COVID-19 vaccines, despite ongoing vaccine and adjuvant research. Here, we evaluated the effectiveness of Astragalus polysaccharide (APS), a bioactive polysaccharide extracted from the traditional Chinese herb Astragalus membranaceus as an immune adjuvant to regulate the efficacy of influenza split vaccine (ISV) and recombinant severe acute respiratory syndrome (SARS)-Cov-2 vaccine in mice. Our data indicated that APS as an adjuvant can facilitate the induction of high levels of hemagglutination inhibition (HAI) titer and specific antibody immunoglobulin G (IgG) and confer protection against the lethal challenge of influenza A viruses, including increased survival and amelioration of weight loss in mice immunized with the ISV. RNA sequencing (RNA-seq) analysis revealed that the NF-κB and Fc gamma R-mediated phagocytosis signaling pathways are essential for the immune response of mice immunized with the recombinant SARS-Cov-2 vaccine (RSV). Another important finding was that bidirectional immunomodulation of APS on cellular and humoral immunity was observed, and APS-adjuvant-induced antibodies persisted at a high level for at least 20 weeks. These findings suggest that APS is a potent adjuvant for influenza and COVID-19 vaccines, and has the advantages of bidirectional immunoregulation and persistent immunity.
Keywords: Adjuvant; Astragalus polysaccharide; Immunomodulation; Influenza vaccine; Recombinant SARS-CoV-2 vaccine.